Press Release Aug 17 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has announced the tentative approval of its ANDA for Trabectedin, a generic version of Yondelis, by the U.S. Food and Drug Administration. This approval pertains to the one milligram per vial presentation of the drug.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
- Press Release Jul 25 2022
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jun 01 2022
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
Later from NATCO Pharma
- Press Release Sep 19 2022
- Press Release Sep 24 2022
- Press Release Oct 04 2022
- Press Release Oct 21 2022
- Press Release Nov 09 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma